Status:
UNKNOWN
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis
Lead Sponsor:
Assiut University
Conditions:
Neonatal SEPSIS
Eligibility:
All Genders
1-50 years
Brief Summary
Neonatal sepsis (NS) is a rather serious but relatively common health problem. Despite recent advances in the treatment of neonatal infection, mortality and comorbidities remain high.
Detailed Description
Neonatal sepsis is a major contributor to an estimated 2.6 million annual deaths and accounts for approximately 3 % of all disability-adjusted life years. The consequences of NS can be minimized by ea...
Eligibility Criteria
Inclusion
- Sepsis was defined as a positive blood culture in infants with clinical and laboratory findings of infection. Manifestations of sepsis include poor suckling, sleepiness, respiratory distress, apnea, poor perfusion, cyanosis, bradycardia, fever or hypothermia, feeding intolerance, and neurological signs (as seizures). Routine sepsis evaluations included complete blood count, C-reactive protein, and blood culture.
Exclusion
- malformations
- prematurity
- Apgar score less than seven
- on antibiotics treatment before the start of the study
Key Trial Info
Start Date :
February 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03795285
Start Date
February 20 2019
End Date
September 30 2019
Last Update
January 8 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.